Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient September 2008 International journal of hematology 88(3):336-40 19.03.2019Class Summary. Ribavirin is licensed by the US Food and Drug Administration (FDA) for the management of RSV bronchiolitis and pneumonia. It has a broad spectrum of antiviral activity in vitro, inhibiting replication of RSV as well as influenza, parainfluenza, adenovirus, measles, Lassa fever, and Hantaan viruses.We report a case of severe parainfluenza (PIV) 3 pneumonia in a hematopoietic stem cell transplant recipient that was successfully treated with oral ribavirin and methylprednisolone. A 42-year-old woman diagnosed with acute myelogenous leukemia (FAB M5a) in first complete remission underwent allogeneic bone marrow transplantation from an HLA-matched unrelated donor in May 2006. In July … 26.06.2013Oral therapy, via nasogastric buy viagra new york tube, with ribavirin (120 mg/die) for 10 days was started during ECMO support. The child also received intravenous γ globulin (IVIG 400 mg/kg/daily for 5 days) in combination with bolus of steroids (methilprednisolone 30 mg/kg/die for 3 days).Ribavirin has not been proven to be efficacious for the treatment of infections caused by parainfluenza virus or human metapneumovirus. 4. Aerosolized ribavirin is contraindicated in patients receiving mechanical ventilation due to concerns regarding compatibility with ventilator components. Ribavirin is pregnancy category X. 5.The prognosis for patients with respiratory syncytial virus (RSV) or parainfluenza virus type 3 (PIV3) respiratory tract infection post allogeneic haematopoietic progenitor cell transplant (HPCT) is historically poor. The use of oral ribavirin (RBV) has not been widely studied in this patient population.Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin Infect Dis 53: 77-80. Citation: Bogdanovich T, Kwak EJ, Silveira FP, Pakstis DL, Lanza P, et al. (2016) Oral Ribavirin Treatment Failure for Severe Parainfluenza TypeRespiratory syncytial virus (RSV) infection is a serious complication post allogeneic stem cell transplant. Aerosolized ribavirin is a commonly used therapy; however, oral ribavirin is an alternative with many advantages. There is paucity in literature regarding treatment outcomes using the oral form. Recently, the immunodeficiency scoring index (ISI) was derived from the largest reported RSV Hemolysis was the most common adverse reaction, occurring in 14% (54/375) of patients. Ribavirin was discontinued in 4% of patients secondary to adverse reactions. Conclusions: Oral ribavirin should be considered for the treatment of NIRVI in immunocompromised adults (malignancy/stem cell transplant or lung transplant) or adults with MERS-CoV.